Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Bullboard Posts
Post by Allt1909on Sep 07, 2020 12:46pm
415 Views
Post# 31517927

Virotek off of their webpage.

Virotek off of their webpage.Virotek Short-listed for COVID-19 Response Challenge at World Economic Forum Wilmette, IL, July 15, 2020 – Virotek Inc. (or the "Company"), a biotech company focused on the development and commercialization of innovative biological based therapeutics for infectious diseseases announced today that the Company has been short-listed for the World Economic Forums COVID-19 Response Challenge on behalf of Top Tier Impact. The final cohort of up to 15 solutions will be announced at the World Economic Forum's Sustainable Development Summit in September 2020. “We are pleased for this recognition on a global scale and in particular for a cause of such magnitude”. Dr. Saeid Babaei, CEO of Virotek commented. “The world is seeing a crisis of unprecedented nature and effects. Virotek’s team is committed to our mission – to provide innovative and sustainable therapeutic solutions by leveraging our powerful artificial intelligence combined with biologics platform in the fight against COVID-19. The impressive international network of collaborators will allows us to accelerate our COVID-19 development program”. World Economic Forum For 50 years, the World Economic Forum has facilitated public-private cooperation to improve the state of the world, adopting a multistakeholder approach to engage leaders in society. UpLink is a response to this changing world order, and it will enable decision-makers within the Forum’s network to engage more deeply with the creativity, innovation and local knowledge at the grassroots level. UpLink is a platform to crowdsource innovations, in an effort to accelerate the delivery of the UN Sustainable Development Goals (SDGs). About Virotek Inc. Virotek is a privately held US-based biotech company focused on the development and commercialization of innovative therapeutics for unmet medical needs. At Virotek we have taken a unique and alternative approach to drug design and development. By applying fast, accurate and cost-effective methods, we have designed anti-SARS-CoV-2 antibodies and peptides for therapeutic intervention of COVID-19. Our the drug discovery program, based in Ontario, Canada starts with deployment of an advanced Artificial Intelligence, machine and deep learning processes combined with two biological platforms of single-domian antibodies and designer peptides leading to optimal lead drug candidate selection.
Bullboard Posts